



Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Grimes, et al.
Serial No. : 10/813,336
Filed : March 29, 2004
For : GASTRIN HORMONE IMMUNOASSAYS
Examiner : To be Assigned
Group Art Unit : 1653

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<u>Algis Anilionis</u> Name of Sender	36,995 PTO Reg. No.
<u>Algis Anilionis</u> Signature	April 15, 2005 Date of Signature

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication and the attached Form PTO/SB/08A as substitute for Form 1449/PTO in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98.



1102865-0046

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits according to 37 C.F.R. §1.97(b)(3). Therefore, no fee is due in connection with this filing. However, should any fee be deemed necessary in connection with this filing, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 23-1703.

Dated: April 15, 2005

Respectfully submitted,

Algis Aulionis

Algis Aulionis, Ph.D.

Reg. No. 36,995

Attorney for Applicant(s)

Customer No. 007470

White & Case LLP

Direct Dial: (212) 819-8248

Enclosures



Approved for use through 07/31/2006 OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

<i>Complete if Known</i>	
Application Number	10/813,336
Filing Date	March 29, 2004
First Named Inventor	Grimes, et al.
Art Unit	1653
Examiner Name	TBA
Attorney Docket Number	1102865-0046

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code ² (<i>if known</i>)			
		5,607,676	3-04-1997	Gevas et al.	
		2003/0082643 A1	5-01-2003	Hudson et al.	
		2003/0232399 A1	12-18-2003	Robertson et al.	
		2003/0049698	3-13-2003	Wang	
		5,580,563	12-03-96	Tam et al.	
		5,110,911	5-5-1992	Samuel et al.	
		5,731,159	3-24-1998	Waldman	
		5,767,242	6-16-1998	Zimmermann et al.	
		5,869,045	2-9-1999	Hellstrom et al.	
		6,187,536 B1	2-13-2001	Weinberg et al.	
		6,251,581 B1	6-26-2001	Ullman et al.	
		6,320,022 B1	11-20, 2001	Cutitta et al.	
		6,696,262 B2	2-24-2004	Härkönen	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)				
		WO 01/77685 A2	10-18-2001			
		WO 2004/023148	03-18-2004			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		SUGANO et al., The Journal of Biological Chemistry, 1986, 11724-11729, Vol. 380	
		VARRO et al., Ann Clin Biochem, 2003, 472-480, Vol. 40	
		RAHIER et al., Biosynthesis of Gastrin, Gastroenterology, 1987, 1146-1152, Vol. 92	

NON PATENT LITERATURE DOCUMENTS

	KOKTHARY et al., Regulatory Peptides, 1987, 71-84, Vol. 17
	ARDILL et al., QJ Med, 1998; 739-742, Vol. 91
	SEVA, et al., Science, 1994, 410-412, Vol. 265
	SMITH et al., The British Journal of Surgery, 1998, 1285-1289, Vol. 85
	TODISCO et al., The Journal of Biological Chemistry, 1995, 28337-28341, Vol. 270
	WATSON et al., Br. J. Cancer, 1989, 554-558, Vol. 59
	VARRO et al., The Journal of Biological Chemistry, 1994, 20764-20770, Vol. 269
	DICKINSON et al., The Journal of Biological Chemistry, 1991, 334-338, Vol. 266
	KELLY et al., Journal of Gastroenterology and Hepatology, 1998, 208-214, Vol. 13
	Rehfeld et al., Cancer Research, 1989, 2840-2843, Vol. 49
	Smith et al., Gut, 2000, 820-824, Vol. 47
	WATSON et al., Cancer Research, 2001, 625-631, Vol. 61
	HUGHES et al., Digestive Diseases, 1976, 201-204, Vol. 21
	JAFFE, et al., Surgery, 1969, 633-639, Vol. 65
	DOCKRAY, et al., The Gastrins: Their Production and Biological Activities, 119-139
	SMITH et al., Alimentary Pharmacology & Therapeutics, 1231-1247, Vol. 14
	DICKINSON et al., Gastroenterology, 1995, 1384-1388, Vol. 109
	REHFELD ET AL., Biochimica et Biophysic Acta, 1972, 364-372, Vol. 285
	NEMETH ET AL., Gut, 1993, 90-95, Vol. 34
	VARNDELL, ET AL., Experientia, 1983, 713-717, Vol. 39
	WATSON, S. Exp. Opin. Invest. Drugs, 1995, 1253-1266, Vol. 4
	WATSON, ET AL., Gastrin Receptors in Gastrointestinal Tumors, 1993, 1-91
	CAPLIN, ET AL., Journal of Hepatology, 1999, 519-526, Vol. 30
	HENWOOD, ET AL., British Journal of Surgery, 2001, 564-568, Vol. 88
	WATSON, ET AL., Int. J. Cancer, 1998, 873-877, Vol. 75
	WATSON, ET AL., Int. Cancer, 1999, 248-254, Vol. 81

NON PATENT LITERATURE DOCUMENTS

	WATSON, ET AL., Cancer Research, 1996, 880-885, Vol. 56	
	WATSON, ET AL., Cancer Research, 2001, 625-631, Vol. 61	
	WATSON, ET AL., Reports, 1991, 866-871, Vol. 83	
	WATSON, ET AL., Growth Enhancing effects of Gastrin, 1998, 554-558	
	WATSON, ET AL., Exp. Opin. Invest. Drugs, 1995, 1253-1266, Vol. 4	
	WATSON, ET AL., Human Progastrin Expression, 1996, 1918-1929, Vol. 98	
	WATSON, ET AL., Exp. Opin. Ther., 2001, 309-317, Vol. 1	
	HOFF, ET AL., Current Opinion in Oncology, 2002, 621-627, Vol. 14	
	GILLIAM, ET AL., EJSO, 2004, 536-543, Vol. 30	
	KOVACS, ET AL, Gastroenterology, 1989, 1406-1413, Vol. 97	
	MAKISHIMA, ET AL., Faseb Journal, 1994, A92, Vol. 8 Abs 535	
	SMITH, ET AL., Clinical Cancer Research, 2000, 4719-4724, Vol. 6	
	HIS, MD, Arch Pathol Lab Med, 2001, 289-294, Vol. 125	
	COLE, Clinical Chemistry, 1997, 2233-2243, Vol. 43	
	FEURLE, ET AL, Pancreas, 1995, 281-286, Vol. 10	
	OHNING, ET AL., Peptides, 1994, 417-587, Vol. 15	
	KOVACS, ET AL., Peptides, 1996, 583-587, Vol. 17	
	OHNING, ET AL., The American Journal Physiological Society, 1996, G470-476	
	SIPPONEN, ET AL., Scand J Gastroenterol, 2002, 785-791, Vol. 7	
	DOCKRAY, ET AL., Gastroenterology, 1975, 222-230, Vol. 68	
	SMITH, ET AL., American Journal Physiology, 1996, R1078-R1084, Vol. 270	
	SMITH, ET AL., American Journal Physiology, 1995, R135-R141, Vol. 286	
	SMITH, ET AL., American Journal Physiology, 1994, R277-283, Vol. 266	
	YANAIHARA, ET AL., Gut Peptides, 1979, 26-33	
	KOVACS, ET AL., American Journal Physiology, 1997, G399-403, Vol. 273 (2 Pt 1).	
	VAANANEN ET AL., European J. Gastrolenterology, 2003, 885-891, Vol. 15 (Pt 8).	

NON-PATENT LITERATURE DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **Applicant's unique citation designation number (optional):** ²See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 to ST.18. "Checkmark to place a check mark here if English language translation is available. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public in this file and is being collected by the USPTO under a statutory obligation. Submission of this information is voluntary. It will take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon individual case. Any comments you may have concerning this burden or any suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.